The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells

Li Wen Hsu; Chin Hsiang Yang; Shigeru Goto; Toshiaki Nakano; Chia Yun Lai; Yu Chun Lin; Ying Hsien Kao; Shu Hui Chen; Yu Fan Cheng; Bruno Jawan; King Wah Chiu; Fu Kai Tsao; Chao Long Chen

doi:10.1016/j.trim.2007.05.008

The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells

Li Wen Hsu, Chin Hsiang Yang, Shigeru Goto, Toshiaki Nakano, Chia Yun Lai, Yu Chun Lin, Ying Hsien Kao, Shu Hui Chen, Yu Fan Cheng, Bruno Jawan, King Wah Chiu, Fu Kai Tsao, Chao Long Chen^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

5 Scopus citations

Abstract

We previously demonstrated that the anti-allergic drug, suplatast tosilate (IPD-1151T), prolonged rat survival after heterotopic heart transplantation (HHT) and suppressed mixed lymphocyte reaction (MLR). In the present study, we investigated the effects of suplatast on T cells, lipopolysaccharides (LPS), or peptidoglycan (PGN)-stimulated cells and dendritic cells (DCs). The addition of suplatast to concanavalin A (ConA) blasts inhibited the proliferation of cells in which the gene expression of T-helper-1 (Th1) and T-helper-2 (Th2) cytokines including interferon (IFN)-γ, interleukin (IL)-2, IL-4, and IL-10 were down-regulated with decreased concentration of the IFN-γ and IL-10 in the supernatants of ConA blast cells. Suplatast also showed down-regulation of the toll-like receptor (TLR)2, TLR4, and CD14 gene expressions on splenocytes stimulated by LPS and PGN, TLR2 or TLR4 agonist, respectively. DCs treated with suplatast expressed lower levels of CD40, CD80, and CD86 and reduced IL-12 production. These results suggest that suplatast may modulate the TLRs on antigen-presenting cells (APCs) and thus block the pathway of Th1/Th2 cytokine production.

Original language	English
Pages (from-to)	108-114
Number of pages	7
Journal	Transplant Immunology
Volume	18
Issue number	2
DOIs	https://doi.org/10.1016/j.trim.2007.05.008
State	Published - 11 2007

Keywords

Antigen-presenting cells
Dendritic cells
Suplatast tosilate
T-helper cytokines
Toll-like receptor

Access to Document

10.1016/j.trim.2007.05.008

Cite this

@article{d6a6c4db1ac74b9ebd498be38f5eb91d,

title = "The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells",

abstract = "We previously demonstrated that the anti-allergic drug, suplatast tosilate (IPD-1151T), prolonged rat survival after heterotopic heart transplantation (HHT) and suppressed mixed lymphocyte reaction (MLR). In the present study, we investigated the effects of suplatast on T cells, lipopolysaccharides (LPS), or peptidoglycan (PGN)-stimulated cells and dendritic cells (DCs). The addition of suplatast to concanavalin A (ConA) blasts inhibited the proliferation of cells in which the gene expression of T-helper-1 (Th1) and T-helper-2 (Th2) cytokines including interferon (IFN)-γ, interleukin (IL)-2, IL-4, and IL-10 were down-regulated with decreased concentration of the IFN-γ and IL-10 in the supernatants of ConA blast cells. Suplatast also showed down-regulation of the toll-like receptor (TLR)2, TLR4, and CD14 gene expressions on splenocytes stimulated by LPS and PGN, TLR2 or TLR4 agonist, respectively. DCs treated with suplatast expressed lower levels of CD40, CD80, and CD86 and reduced IL-12 production. These results suggest that suplatast may modulate the TLRs on antigen-presenting cells (APCs) and thus block the pathway of Th1/Th2 cytokine production.",

keywords = "Antigen-presenting cells, Dendritic cells, Suplatast tosilate, T-helper cytokines, Toll-like receptor",

author = "Hsu, {Li Wen} and Yang, {Chin Hsiang} and Shigeru Goto and Toshiaki Nakano and Lai, {Chia Yun} and Lin, {Yu Chun} and Kao, {Ying Hsien} and Chen, {Shu Hui} and Cheng, {Yu Fan} and Bruno Jawan and Chiu, {King Wah} and Tsao, {Fu Kai} and Chen, {Chao Long}",

year = "2007",

month = nov,

doi = "10.1016/j.trim.2007.05.008",

language = "英语",

volume = "18",

pages = "108--114",

journal = "Transplant Immunology",

issn = "0966-3274",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells

AU - Hsu, Li Wen

AU - Yang, Chin Hsiang

AU - Goto, Shigeru

AU - Nakano, Toshiaki

AU - Lai, Chia Yun

AU - Lin, Yu Chun

AU - Kao, Ying Hsien

AU - Chen, Shu Hui

AU - Cheng, Yu Fan

AU - Jawan, Bruno

AU - Chiu, King Wah

AU - Tsao, Fu Kai

AU - Chen, Chao Long

PY - 2007/11

Y1 - 2007/11

N2 - We previously demonstrated that the anti-allergic drug, suplatast tosilate (IPD-1151T), prolonged rat survival after heterotopic heart transplantation (HHT) and suppressed mixed lymphocyte reaction (MLR). In the present study, we investigated the effects of suplatast on T cells, lipopolysaccharides (LPS), or peptidoglycan (PGN)-stimulated cells and dendritic cells (DCs). The addition of suplatast to concanavalin A (ConA) blasts inhibited the proliferation of cells in which the gene expression of T-helper-1 (Th1) and T-helper-2 (Th2) cytokines including interferon (IFN)-γ, interleukin (IL)-2, IL-4, and IL-10 were down-regulated with decreased concentration of the IFN-γ and IL-10 in the supernatants of ConA blast cells. Suplatast also showed down-regulation of the toll-like receptor (TLR)2, TLR4, and CD14 gene expressions on splenocytes stimulated by LPS and PGN, TLR2 or TLR4 agonist, respectively. DCs treated with suplatast expressed lower levels of CD40, CD80, and CD86 and reduced IL-12 production. These results suggest that suplatast may modulate the TLRs on antigen-presenting cells (APCs) and thus block the pathway of Th1/Th2 cytokine production.

AB - We previously demonstrated that the anti-allergic drug, suplatast tosilate (IPD-1151T), prolonged rat survival after heterotopic heart transplantation (HHT) and suppressed mixed lymphocyte reaction (MLR). In the present study, we investigated the effects of suplatast on T cells, lipopolysaccharides (LPS), or peptidoglycan (PGN)-stimulated cells and dendritic cells (DCs). The addition of suplatast to concanavalin A (ConA) blasts inhibited the proliferation of cells in which the gene expression of T-helper-1 (Th1) and T-helper-2 (Th2) cytokines including interferon (IFN)-γ, interleukin (IL)-2, IL-4, and IL-10 were down-regulated with decreased concentration of the IFN-γ and IL-10 in the supernatants of ConA blast cells. Suplatast also showed down-regulation of the toll-like receptor (TLR)2, TLR4, and CD14 gene expressions on splenocytes stimulated by LPS and PGN, TLR2 or TLR4 agonist, respectively. DCs treated with suplatast expressed lower levels of CD40, CD80, and CD86 and reduced IL-12 production. These results suggest that suplatast may modulate the TLRs on antigen-presenting cells (APCs) and thus block the pathway of Th1/Th2 cytokine production.

KW - Antigen-presenting cells

KW - Dendritic cells

KW - Suplatast tosilate

KW - T-helper cytokines

KW - Toll-like receptor

UR - http://www.scopus.com/inward/record.url?scp=36048944463&partnerID=8YFLogxK

U2 - 10.1016/j.trim.2007.05.008

DO - 10.1016/j.trim.2007.05.008

M3 - 文章

C2 - 18005853

AN - SCOPUS:36048944463

SN - 0966-3274

VL - 18

SP - 108

EP - 114

JO - Transplant Immunology

JF - Transplant Immunology

IS - 2

ER -

The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this